SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways

Huairui Yuan1, Ying Han1, Xuege Wang1

  • 1CAS Key Laboratory of Tissue Microenvironment and Tumor, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China.

Cancer Cell
|July 4, 2020
PubMed

Insights

SETD2 delays prostate cancer (PCa) metastasis by methylating EZH2, promoting its degradation. This SETD2-EZH2 pathway integrates metabolic and epigenetic signals to restrict PCa spread.

Area of Science:

  • Epigenetics
  • Cancer Biology
  • Metabolic Signaling

Background:

  • SETD2 and EZH2 catalyze opposing histone marks (H3K36me3 and H3K27me3).
  • The molecular interplay between SETD2 and EZH2 in prostate cancer (PCa) metastasis is not well understood.

Purpose of the Study:

  • To investigate the role of SETD2 in regulating EZH2 activity and its impact on PCa metastasis.
  • To elucidate the mechanism by which SETD2-EZH2 axis influences prostate cancer progression.

Main Methods:

  • Assessed SETD2-mediated methylation of EZH2 in prostate cancer cells.
  • Utilized mouse models with specific SETD2 and EZH2 mutations.
  • Investigated the role of AMPK signaling and FOXO3 in regulating SETD2 expression.

Main Results:

  • SETD2 methylates EZH2, leading to its degradation, thereby delaying PCa metastasis.
  • SETD2 deficiency promotes a metastatic phenotype by inducing Polycomb-repressive chromatin.
  • Mutant EZH2 or SETD2 impaired in EZH2 binding leads to metastatic PCa.
  • Metformin-stimulated AMPK signaling upregulates SETD2 expression via FOXO3.

Conclusions:

  • The SETD2-EZH2 axis acts as a crucial regulator, restricting prostate cancer metastasis.
  • This axis integrates metabolic cues (via AMPK/FOXO3) and epigenetic modifications to control cancer progression.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.3K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.5K